AsianScientist (Dec. 12, 2013) – IXICO plc has signed a memorandum of understanding with the Beijing Union Medical and Pharmaceutical General Corporation (UMP) to work on improving the diagnosis and treatment of dementia in China.
UMP is a fully owned subsidiary and innovation arm of the Chinese Academy of Medical Sciences (CAMS).
IXICO and UMP plan to jointly deploy a neuroimaging informatics platform in China for dementia diagnosis and to identify new dementia treatments.
It is estimated that in China a significant majority of the dementia population remain undiagnosed and currently an estimated six to ten million people have dementia (20-25 percent of the world’s dementia cases), 60 percent of which have Alzheimer’s disease.
Furthermore, the total annual healthcare costs for dementia are estimated at £5.5 billion and the annual loss to the economy is around £9 billion. The incidence rate of dementia is estimated to double over the next 20 years as the Chinese population ages and by 2040, the population with dementia in China is expected to equal the total in all high income countries.
“There is a large unmet need in China for earlier and more accurate diagnosis of dementia. China represents a large opportunity for IXICO: there are more dementia sufferers in China than in any other country in the world. This MOU is an important initial step to enable IXICO technology to be used to support improved dementia diagnosis and the development of new treatments for China’s current and future dementia sufferers,” said Professor Derek Hill, CEO of IXICO.
Source: IXICO plc.
Disclaimer: This article does not necessarily reflect the views of AsianScientist or its staff.